Is ticagrelor worth its high cost and side-effects?

References

• Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–177.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [Internet]. US: Center for Drug Evaluation and Research. Ticagrelor medical review. 2011 [cited Apr]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000MedR.pdf
   Google Scholar
• Serebruany VL, Atar D. Viewpoint: central adjudication of myocardial infarction in outcome-driven clinical trials-common patterns in TRITON, RECORD, and PLATO? Thromb Haemost. 2012;108:412–414.
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Held C, Wojdyla DM, et al. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2014;63:1493–1499.
   PubMed Web of Science ®Google Scholar
• Goto S, Huang CH, Park SJ, et al. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome. Circ J. 2015;79:2452–2460.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Tomek A, Pya Y, et al. Inferiority of ticagrelor in the PHILO trial: play of chance in East Asians or nightmare confirmation of PLATO-USA? Int J Cardiol. 2015;215:372–376.
   Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–1800.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Bonaca MP, Bansilal S, et al. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67:2732–2740.
   PubMed Web of Science ®Google Scholar
• Magnani G, Storey RF, Steg G, et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J. 2016;37:400–408.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol. 2016;67:2720–2728.
   Google Scholar
• Hiatt WR, Fowkes FG, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376:32–40.
   PubMed Web of Science ®Google Scholar
• Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375:35–43.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577–2585.
   PubMed Web of Science ®Google Scholar
• Ma TK, Lam YY, Tan VP, et al. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol. 2011;72:697–706.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2007;345:494–502.
   Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006;48:931–938.
   PubMed Web of Science ®Google Scholar
• Mangiacapra F, Muller O, Ntalianis A, et al. Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol. 2010;106:1208–1211.
   PubMed Web of Science ®Google Scholar
• Patti G, Bárczi G, Orlic D, et al. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty-Myocardial Infarction) randomized study. J Am Coll Cardiol. 2011;58:1592–1599.
   PubMed Web of Science ®Google Scholar
• Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010;122:2131–2141.
   PubMed Web of Science ®Google Scholar
• Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38:3070–3078.
   PubMed Web of Science ®Google Scholar
• Sahlén A, Varenhorst C, Lagerqvist B, et al. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart J. 2016;37:3335–3342.
   PubMed Web of Science ®Google Scholar
• Redfors B, Volz S, Angeras O, et al. Ticagrelor is not superior to clopidogrel in patients with acute coronary syndrome – a report from SCAAR. J Am Coll Cardiol. 2017;70:C116–C117.
   Web of Science ®Google Scholar
• Olier I, Sirker A, Hildick-Smith DJR, on behalf of the British Cardiovascular Intervention Society and the National Institute for Cardiovascular Outcomes Research, et al. Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention. Heart. 2018. DOI: 10.1136/heartjnl-2017-312366
   Web of Science ®Google Scholar
• Serebruany VL, Tomek A. Missed bleeding events after ticagrelor in PEGASUS trial: massive non-compliance, information censoring, or both? Int J Cardiol. 2016;215:214–216.
   Web of Science ®Google Scholar
• Serebruany VL, Tomek A, Pokov AN, et al. Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner? Exp Rev Cardiovasc Ther. 2015;13:1333–1344.
   PubMed Web of Science ®Google Scholar
• Belchikov YG, Koenig SJ, Dipasquale EM. Potential role of endogenous adenosine in ticagrelor-induced dyspnea. Pharmacotherapy. 2013;33:882–887.
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Faioni EM. Why does ticagrelor induce dyspnea? Thromb Haemost. 2012;108:412–414.
   Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Moulias A, et al. Long-term P2Y12-receptor antagonists in post-myocardial infarction patients facing a new trilemma? J Am Coll Cardiol. 2016;68:1223–1232.
   Web of Science ®Google Scholar